CABINET: Cabozantinib in Advanced pNET and Carcinoid Tumors
CABINET Randomized, Double-Blinded Phase III Study of Cabozantinib Versus Placebo in Patients with Advanced NETs After Progression on Prior Therapy
CLINICALTRIALS.GOV IDENTIFIER: NCT03375320
SPONSOR: National Cancer Institute (NCI)
UPDATE - Aug 24, 2023
The Alliance for Clinical Trials in Oncology announced that the CABINET trial (NCT03375320) showed positive findings with cabozantinib having efficacy.
The CABINET trial is a phase 3 randomized, double-blinded study evaluating cabozantinib compared with placebo in patients with advanced pancreatic neuroendocrine tumors (PNET) or advanced extra-pancreatic neuroendocrine tumors (carcinoid tumors) who experienced progression after prior systemic therapy.
The trial is now being stopped early. It will be unblinded, meaning the patients will find out if they have been receiving placebo and those who have will have the possibility of receiving cabozantinib. The findings will be discussed with the U.S. Food and Drug Administration. Detailed results from the trial will be presented at an upcoming scientific meeting.
Dr. Jennifer Chan Discusses CABINET: Cabozantinib
This phase III trial studies cabozantinib to see how well it works compared with placebo in treating patients with neuroendocrine or carcinoid tumors that have spread to other places in the body (advanced). Cabozantinib is a chemotherapy drug known as a tyrosine kinase inhibitor, and it targets specific tyrosine kinase receptors that, when blocked, may slow tumor growth.
This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information.
Jennifer A Chan, MD, MPH
Alliance for Clinical Trials in Oncology and National Cancer Institute (NCI)